Poseida Therapeutics, Inc. is searching for an outstanding Scientist to join our Nanotechnology group in San Diego, CA. This position offers an excellent opportunity to develop delivery tools for gene therapy applications in an exciting and dynamic environment focused on cutting-edge gene insertion and editing technology. This person will develop nucleic acid constructs for ex vivo and in vivo gene therapy applications, perform mechanistic studies using various nanoparticle-based delivery systems, and provide support for screening, formulation, and chemistry teams.
These may include but are not limited to:
- Assume responsibility for designing and synthesizing DNA and mRNA constructs used by Nanotechnology group for routine screening and MoA work
- Serve as molecular biology SME for the Nanotechnology group, and interface with company-wide molecular biology resources
- Conduct independent research directed toward optimizing Poseida’s gene editing and gene insertion tools and novel non-viral delivery vehicles
Requirements, Knowledge, Skills and Abilities
- PhD in molecular biology, cell biology, bioengineering, or related field with at least 2 years of relevant experience, or MS and 10 years of experience working in a biopharmaceutical drug discovery/development setting (an equivalent of education and experience may be considered).
- Demonstrated mastery of routine molecular biology techniques, including molecular cloning, PCR, qRT-PCR, DNA sequencing, mRNA and DNA sequence optimization, in vitro transcription, and use of gene editing/insertion systems
- Strong experience in cell-based models and techniques, including primary culture (lymphocytes, stem cells, or hepatocytes), flow cytometry, live cell imaging, Western blotting, in situ hybridization, and immunostaining.
- Ability to work on multiple projects at once
Who We Are and What We Do
Poseida is a San Diego based biotechnology leader in the development of cell and gene therapies. We have built a wholly-owned pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumors. Here at Poseida we are constantly innovating and growing as we advance our CAR-T therapies in the clinic and our gene therapies currently under development. The Poseida team is passionate about the impact we are making in developing treatments, or even cures, for patients with cancer or other genetic diseases.
The company’s CAR-T product candidates are manufactured with Poseida’s non-viral piggyBac® DNA Modification System, resulting in a high percentage of stem cell memory T cells (TSCM). Tscm cells are the only T cells that are self-renewing and long-lived, potentially resulting in product candidates that are more efficacious, less toxic and more durable. Poseida is currently developing the following CAR-T product candidates:
- P-BCMA-101 is an autologous CAR-T therapy for the treatment of relapsed/refractory multiple myeloma, currently enrolling patients for a Phase 2 registrational trial with initial dosing expected in the first half of 2019.
- P-PSMA-101 is an autologous CAR-T product candidate targeting PSMA-specific cancer cells in castrate resistant prostate cancer, with filing of an IND anticipated in the second half of 2019.
- P-BCMA-ALLO1 is an allogeneic, or universal donor, CAR-T product candidate, manufactured using Poseida’s proprietary Cas-CLOVER™ site specific gene editing system and is being developed as a treatment for relapsed/refractory multiple myeloma, with an IND filing anticipated by late 2019 or early 2020.
- P-MUC1C-101 is an autologous CAR-T product candidate in late-stage preclinical development for numerous solid tumor indications, including ovarian, breast, lung, colorectal, pancreatic and renal cancers, with filing of an IND anticipated in 2020.
Poseida plans to broadly advance its current CAR-T programs and emerging pipeline programs, including gene therapies for orphan genetic diseases.
TO APPLY SEND YOUR RESUME AND COVER LETTER TO JOBS@POSEIDA.COM.